Skip to main content

Table 5 Comparisons of LDLC change between statin tolerant and intolerant groups

From: Efficacy and safety of proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors, alirocumab and evolocumab, a post-commercialization study

 

Statin tolerant (n = 23)

Statin intolerant (n = 46)

LS means1 ± SE of absolute change in LDLC (mg/dl)

−86 ± 8

−75 ± 5

 Group differences

p = .21

LS means1 ± SE of percentage change in LDLC (%)

-58 ± 7

−48 ± 4

 Group differences

p = .19

  1. 1Least Square means for statin taking and not taking groups, adjusted for PCSK9 treatment (2 groups), treatment duration, age, BMI, race, gender, HeFH (yes-no), CVD (yes-no) and LDLC at entry.
Back to article page

Lipids in Health and Disease

ISSN: 1476-511X